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The importance of diabetes in the epidemiology of cardiovascular diseases cannot be overemphasized. About one third of acute
myocardial infarction patients have diabetes, and its prevalence is steadily increasing. The decrease in cardiac mortality in people
withdiabetes is laggingbehind thatofthe generalpopulation.Cardiovasculardiseaseisa broad term which includes anycondition
causing pathological changes in blood vessels, cardiac muscle or valves, and cardiac rhythm. The ECG oﬀers a quick, noninvasive
clinical and research screen for the early detection of cardiovascular disease in diabetes. In this paper, the clinical and research
value of the ECG is readdressed in diabetes and in the presence of cardiac autonomic neuropathy.
1.Introduction
T he importance of diabetes, both type 1 and type 2, in the
epidemiology of cardiovascular diseases cannot be overem-
phasized. About one third of acute myocardial infarction
patients have diabetes, the prevalence of which is steadily
increasing [1]. The decrease in cardiovascular mortality in
people with diabetes is laggingb e h i n dc o m p a r e dt ot h a to f
the general population [2]. Cardiovascular disease is a broad
term which includes any condition causing pathological
changes in blood vessels, cardiac muscle or valves, and
cardiac rhythm. Diabetic cardiomyopathy, although a part
of the diabetic atherosclerosis process, is a distinct clinical
entityand maybeindependentofthecoexistenceofischemic
heart disease, arterial hypertension, or other macrovascular
complications [3]. Its pathological substrate is characterized
b yt h ep r e s e n c eo fm y o c a r d i a ld a m a g e ,d i s t u r b a n c eo ft h e
management of the metabolic cardiovascular load, and
cardiac autonomic neuropathy (CAN) [4]. These alterations
make the diabetic heart susceptible to ischemia and less able
to revive from an ischemic attack.
To philosophers, the question about which came ﬁrst,
the chicken or the egg evoked the questions of how life and
the universe in general began [5]. Translating this causality
dilemma in the language of “cardiovascular diabetology,”
from one hand, diabetes is considered an equivalent to
coronary heart disease, and from the other hand, coronary
heart disease accounts for 65% to 80% of deaths in patients
with diabetes [6]. However, the merits of screening clinically
asymptomatic patients with diabetes for either the presence
of coronary atherosclerosis or silent myocardial ischemia
remain controversial [7]. Some observers advocate for the
application of noninvasive screening testing only among
patients with diabetes in whom the diagnosis of coronary
heart disease is highly probable due to the presence of
signiﬁcant clinical coronary heart disease risk factors [8].
Thus, noninvasive screening testing will probably serve in
the identiﬁcation of patients with diabetes and serious
coronary obstruction, in which coronary revascularization
and optimummedical therapy may be considered in orderto
achieve the avoidance of a fatal cardiac event. Nevertheless,
another physician observational group sustains the eﬃcacy
of cardiovascular testing in clinically asymptomatic people
with diabetes, exactly because of either the presence of atypi-
calsymptoms orthe absenceofsymptoms oftenencountered
in the presence of a pathophysiological substrate equal to2 Experimental Diabetes Research
coronary heart disease, which, compared to the general
population, diﬀerentiates signiﬁcantly the medical approach
in patients with diabetes [9].
Over the past decades, the 12-lead classic ECG has main-
tained its special signiﬁcance for the diagnosis and triage of
patients with suspected coronary heart disease and has been
widespread utilized both in the diagnostic and the researcher
quest as a detection and screening tool of myocardial injury.
In the present paper, we aimed to summarize the ECG
signs and patterns in terms of their relevance ﬁrstly to the
clinician to help with the everyday diagnosis, screening, and
timely decision making, but also secondly in terms of their
application in the future and ongoing research. For this
purpose, the medical literature on ECG manifestations of
diabetes and cardiac autonomic neuropathy was systemati-
cally searched. We used the PubMed and Embase databases
up to January 2011 using the following keywords: “diabetes,”
“cardiomyopathy,” “cardiac autonomic neuropathy,” “neu-
ropathy,” “autonomic dysfunction,” “electrocardiography,”
“vectorcardiography,” “QT interval,” “spatial QRS-T angle,”
“pattern,” “signs,” “markers,” “diagnosis,” and “treatment”
aloneand incombinationtoretrieve availableliteraturedata.
All types of articles (randomized controlled trials, original
studies, review articles, case reports) in humans and animals
published in English, German, French, and Romanian
language were included. Publications were studied in full.
2.TheECGasa Diagnostic Toolin
DiabeticCardiomyopathy
2.1. The ECG Pattern in Early Diabetic Cardiomyopathy. In
the everyday clinical practice, the ECG oﬀers a quick,nonin-
vasive clinical and research screen for the early detection of
cardiovascular disease. Reactive hypertrophy, intermediary
ﬁbrosis, and structural and functional changes of the small
coronary vessels, especially in the basal area of the left
ventricle, have frequently been observed in patients with
diabetes and diabetic cardiomyopathy, even when cardiac
involvement is clinically not yet evident [10].
The preclinical phase of diabetic cardiomyopathy may be
diagnosedbydemonstratingexercise-inducedleftventricular
dysfunction, even when the resting cardiac function is still
adequate [11]. The early stage of diabetic cardiomyopa-
thy may already be associated with a range of metabolic
abnormalities and even with abnormalities in diastolic
function [12]. However, frequently no structural cardiac
abnormalities can be identiﬁed at this stage, and the often
subtle ECG alterations may be the only way to diagnose early
diabetic cardiomyopathy.
Resting 12-lead ECG may show alterations of P-wave
indexes (i.e. increased P-wave duration, prolongation of the
PR interval, and enlarged P-wave terminal force), indicating
besides atrioventricular conductionalterations, and arrhyth-
mia, increased accumulated pericardial fat [13], which
attributes to the progression of coronary atherosclerosis and
is an independent risk factor for stenotic coronary artery
disease [14]; increased Cornell voltage [15, 16] or Sokolow-
Lyon voltage and left ventricular strain pattern [17, 18]m a y
also be present indicating early left ventricular hypertrophy.
Figure 1: A 45-year-old man underwent routine blood tests
that revealed a fasting blood glucose value of 125mg/dL and
hemoglobin A1c of 6.5%, resulting in the diagnosis of type 2
diabetes. Resting 12-lead ECG showed deep S-wave in Lead III and
R-wave in Lead aVL, indicating early left ventricular hypertrophy.
Cardiac autonomic functional testing diagnosed the presence of
cardiac autonomic neuropathy. Stress ECG demonstrated a 2-mm
depression of the ST segment. Transthoracic 2D Doppler echocar-
diographyperformed revealedpresence ofmildleftventricular(LV)
hypertrophy (LV wall mass index = 126g/m2) and an abnormal
relaxation pattern (E/A < 1) with preserved LV systolic function
(LV ejection fraction >60%). The patient was given strict diet
restrictions; oral antidiabetic medication, b-blocker, statin and
aspirin therapy was initiated, together with lifestyle measures to
control cardiovascular risk factors. Throughout a 6-year follow-up,
his diabetes remains well controlled, and the ECG unchanged.
Figure 1 illustrates an example of the ECG pattern in early
diabetic cardiomyopathy with presence of left ventricular
hypertrophy in a patient newly diagnosed with type 2
diabetes.
2.2. The ECG Pattern in Silent Myocardial Ischemia and Its
Prognostic Value. Silent myocardial ischemia is a common,
underrecognized condition that is associated with an adverse
prognosis. It is a marker of signiﬁcant underlying coronary
heart disease and, therefore, of future cardiovascular events
[19]. Silent myocardial infarction is more prevalent in
type 2 diabetes and occurs in greater than one in ﬁve
clinically asymptomatic patients with type 2 diabetes [20].
Resting ECG abnormalities, erectile dysfunction, periph-
eral vascular disease, and cardiac autonomic neuropathy
are among the main clinical markers predictive of silent
myocardial ischemia, and their presence should prompt
further investigation in clinically asymptomatic patients
with diabetes [21]. Carotid or peripheral arterial disease,
proteinuria, male gender, age > 60 years, and presence of
two or more of the following cardiovascular risk factors:
smoking, microalbuminuria, dyslipidemia, hypertension, a
family history of premature cardiac disease, and cardiac
autonomic neuropathy, have been demonstrated to be
the best current predictors of silent myocardial ischemia
and silent coronary arterial stenosis [22]. New markers,
such as adhesion molecules, Lipoprotein(a), inﬂammation
parameters or homocysteine, osteoprotegerin and markers
of endothelium function assessment might also be of further
help in the future [22, 23].
A recent 5-year follow-up study in patients with type
2 diabetes, aged 50–75 years, without known or suspectedExperimental Diabetes Research 3
coronary heart disease, compared traditional, inﬂammatory
and prothrombotic emerging cardiac risk factors with pres-
ence of CAN as a predictor for silent myocardial ischemia.
Silent myocardial ischemia was diagnosed by stress testing,
and presence of CAN was the strongest predictor of ischemia
in both sexes together with male gender and duration of
diabetes. Among the ECG markers, ischemic adenosine-
induced ST-segment depression with normal perfusion was
associated with a 3-fold increased risk of silent myocardial
ischemia in women [24].
Isolated minor nonspeciﬁc ST-segment and T-wave
abnormalities, indicating increased risk for coronary heart
disease mortality and primary arrhythmic death can be
present in the resting ECG in elderly (≥70 years) patients
with diabetes [25]. Exercise microvolt T-wave alternans
identify sudden cardiac death risk and have been identiﬁed
in the ECGs of postmyocardial infarction patients with
diabetes[26].ComputerizedECGmeasuresofrepolarization
abnormality and complexity, that is, ST-segment depression
≥50µV, QT interval corrected for heart rate (QTc) >460ms,
and increased principal component analysis (PCA) of the
ratio of the second to ﬁrst eigenvalues of the T-wave vector
(PCA ratio) can predict silent myocardial ischemia and
all-cause mortality in patients with type 2 diabetes [27].
Finally, unrecognized Q-wave myocardial infarction can be
present in patients with type 2 diabetes, hypertension, and
microvascular complications [28]. Figure 2 illustrates the
presence of silent myocardial ischemia in the ECG pattern
of a clinically asymptomatic patient with type 2 diabetes and
cardiac autonomic dysfunction.
Diabetes was recently demonstrated as the strongest
predictor of atrial ﬁbrillation progression and patients with
diabetes and CAN frequently have asymptomatic episodes
of atrial ﬁbrillation with silent arrhythmia progression [29].
Moreover, patients with type 2 diabetes and atrial ﬁbrillation
may be at substantially higher risk of death of any cause
compared with those without atrial ﬁbrillation or without
diabetes [30]. Therefore, atrial ﬁbrillation pattern in patients
with diabetes should be regarded as a prognostic marker of
adverse outcome and prompt aggressive management of all
risk factors is required [30].
In clinically asymptomatic patients with type 2 diabetes
and a normal resting ECG, exercise testing is the ﬁrst
choice for screening for silent myocardial ischemia, whereas
thallium scintigraphy with dipyridamole can be performed
if exercise testing is not possible or is inconclusive [31].
The accuracy of stress ECG is 79% compared to coronary
arteriography which is considered as the screening golden
standard [32]. By combining stress ECG with myocardial
scintigraphy, the detection of more patients with diabetes
and coronary artery stenoses can be eﬀected and a higher
prediction of cardiovascular events (95.4%) achieved.
However, the ECG stress test has a good negative predictive
value for cardiac events (97%), it is cheaper, and should,
therefore, be proposed ﬁrst [33].
Ischemia ECG-stress test pattern is among the signiﬁcant
predictors of cardiac events (4-fold increased risk in abnor-
malresponse),andmyocardialscintigraphyhas anequalpre-
dictive value, followed by presence of peripheral or carotid
Figure 2: Presence of silent myocardial ischemia in the resting
ECG of a middle-aged (50 years), clinically asymptomatic female
patient with type 2 diabetes. Mean duration of diabetes was 4
years and the patient was under oral antidiabetic medication with
an HbA1c <7%. The patient was obese (BMI > 30kg/m2), with
central fat distribution (waist circumference > 88cm), without a
history of hypertension, or of coronary heart disease, but with
dyslipidemia and presence of microalbuminuria. She smoked 25
packs of cigarettes/year. Cardiac autonomic functional testing
revealed increased cardiac sympathetic activity and parasympa-
thetic withdrawal.
occlusive arterial disease (10-fold increased risk) and ﬁnally
coronary stenoses (27-fold increased risk in their presence)
[34]. One recent prospective study examined the association
between exercise ECG responses and mortality in 2.854
men (mean age 50 years) with diabetes who had previously
completed a maximal treadmill exercise test and who did not
have cardiovascular disease history at baseline. During a 16-
yearfollow-upanabnormalandevenequivocalexerciseECG
response was associated with a statistically signiﬁcant 2-fold
higher risk for all-cause and cardiovascular morbidity and
mortality, independently of physical ﬁtness and other tradi-
tional cardiac risk factors, such as hyperglycemia, smoking,
body mass index, hypercholesterolemia, hypertension, and a
family history of cardiovascular disease or diabetes. Fit men
had a higher survival rate than did unﬁt men [35].
The use of screening before an exercise training pro-
gram for asymptomatic patients with type 2 diabetes is
considered justiﬁable [36]. Several recent prospective studies
have addressed the value of screening for coronary heart
disease in clinically asymptomatic patients with diabetes
[25, 37, 38]. The overall message of these studies is that
despite detection of silent myocardial ischemia in a notable
proportion of patients with diabetes, the dynamic patho-
physiological and clinical nature of myocardial ischemia, the
prohibitive cost of screening all asymptomatic patients, and
the proven eﬃcacy of primary preventive strategies would
ﬁnallymandateimplementationofbetterclinicalriskstratiﬁ-
cation strategies for identifying increased at-risk individuals.
However, the best strategy that would allow proper patient
selection through logical stepwise approaches to screening
still remains to be determined. Whether that strategy would
alter patients outcome when added to rigorously implement
primary preventive measures also waits to be answered.
2.3. QT Interval as an Endpoint in Diabetes Trials and Its
Prognostic Value. From QT interval parameters, both the QT4 Experimental Diabetes Research
dispersion (calculated as the mean diﬀerence between the
QT maximum and the QT minimum interval in all ECG
leads) and the QTc maximum have been demonstrated as
independent predictors of cardiovascular mortality (for each
10-ms increment in QT dispersion, 1.5-fold increased risk
for cardiovascular mortality). Excluding patients with prior
cardiac disease did not change signiﬁcantly the prognostic
performance of QT dispersion but decreased that of QTc
maximum [39]. An earlier study also found QT dispersion
to be the most important independent predictor (3-fold
increased risk) of total mortality and also an independent
predictor of cardiac and cerebrovascular mortality [40];
however, these observations were not further conﬁrmed in
al a t e rs t u d y .
QTc interval >460ms has been associated with a 2-fold
increased cardiovascular and all-cause mortality risk in a 5-
year prospective population study in individuals with type 2
diabetes. ST-segment depression ≥2mmandaPCAratioof
the T-wave vector >32% in women and >25% in men were
also independent predictors of mortality (4-fold and 3-fold
increased risk for each ECG alteration, resp.) [41].
A signiﬁcant correlation has been demonstrated between
the QT interval duration and the amount of coronary
calcium measured by coronary artery calciﬁed plaque; this
association was mainly driven by the prolongation of the
QRS interval and not of the JT interval duration. The
associationbetweenabnormalmyocardialrepolarizationand
coronary artery disease was found to be more signiﬁcant in
men than in women with diabetes [42].
2.4.TheECGPatterninType 1DiabetesandCAN:Similarities
and Diﬀerences. In type 1 diabetes, decreased parasympa-
thetic to increased sympathetic tone ratio, clinically man-
ifested by supraventricular tachycardia, and electrocardio-
graphically evidenced by the shortening of the ventricular
activation time, as well as diﬀerences in the depolarization
and the repolarization ECG-pattern, have been revealed
with increased QT and QT dispersion intervals, as well as
with the shortening of the QRS interval [43]. Recently, it
was demonstrated that during spontaneous hypoglycemia in
patientswithtype1diabetes, QTcinterval canbe moderately
increased [44], whereas glucose-QTc association is reported
to diﬀer among individuals with type 1 diabetes. Moreover,
hypoglycemia unawareness was demonstrated to be the
only independent predictor of the glucose-QTc association’s
individual strength in patients with type 1 diabetes [45].
I nt h eE u r o p ea n dD i a b e t e s( E U R O D I A B )s t u d yo n
patients with type 1 diabetes with a normal QTc interval
at baseline, the cumulative incidence of prolonged QTc
interval after the 7-year follow-up was 19% and was 2-fold
higher in women than in men. Seven-year incidence of QTc
prolongation was associated at baseline with older age, phys-
ical inactivity, arterial hypertension, dyslipidemia (assessed
by lower high-density lipoprotein cholesterol levels), pres-
ence of peripheral neuropathy, and coronary heart disease.
Independent predictors of increased QTc-prolongation risk
were female gender, higher values of glycated hemoglobin
A1c (HbA1c), and systolic blood pressure levels, whereas
physical activity and normal body mass index were the main
protective factors [46].
In the WHO Multinational Study of Vascular Disease in
Diabetes in Switzerland, during a follow-up duration of 23
years, 523 patients with diabetes (221 with type 1 diabetes,
and 302 patients with type 2 diabetes) were studied and
the association of QTc interval with total, cardiovascular,
and ischemic heart disease mortality was evaluated.Diﬀerent
results were noted among the studied patients. In subjects
with type 1 diabetes, QTc was associated with an increased
risk of all-cause mortality (hazard ratio: 1.2-fold increased
risk per 10ms increase in QTc interval) and mortality due
to cardiovascular disease. Findings for subjects with type
2d i a b e t e sw e r ed i ﬀerent: only increased heart rate and
not QTc interval was associated with total mortality, and
mortality due to cardiovascular, as well as ischemic heart
disease (hazard ratio: 1.3-fold increased risk per 10 beats
increase per min). Therefore, QTc interval was signiﬁcantly
correlated with long-term mortality in subjects with type 1
diabetes, whereas it was not related with increased mortality
risk in subjects with type 2 diabetes [47]. QTc interval was
considered as a marker of cardiac autonomic dysfunction,
and this diﬀerence between the two types of diabetes was
attributed to the greater importance of CAN noted in
patients with type 1 rather than in patients with type 2
diabetes [48]. However, it may also be related to the recently
described “electromechanical window” which portrays the
temporal diﬀerence between the electrical and mechanical
events of the heart and has currently been demonstrated as
comprising a potential predictive value for the occurrence of
arrhythmias in cardiac autonomic dysfunction [49].
The EURODIAB Insulin-Dependent Diabetes Melli-
tus Complications Study (EURODIAB IDDM) investigated
3.250 patients with type 1 diabetes and average diabetes
duration of more than 30 years; the prevalence of left
ventricular hypertrophy was found to be 3 times greater
than that reported in the general population of similar age.
Moreover, the prevalence of left ventricular hypertrophy was
2-fold higher in women than in men, independent of well-
known cardiovascular risk factors, that is, arterial hyperten-
s i o n ,o b e s i t y ,a n dp h y s i c a li n a c t i v i t y .T h e2 - f o l dh i g h e rr i s k
of left ventricular hypertrophy in women was signiﬁcantly
associated with higher serum triglycerides, central obesity
(waist circumference > 88cm), hypertension, and presence
of coronary heart disease. Moreover, prolongation of the
QTc interval was signiﬁcantly associated with left ventricular
hypertrophy prevalence in both sexes; however, this was not
further validated for QT dispersion [50].
In the Losartan Intervention For Endpoint reduction
in hypertension (LIFE) study of 9.000 patients with hyper-
tension, but without diabetes, during the 5-year follow-up,
regression or persistent absence of left ventricular hypertro-
phy on the ECG pattern during antihypertensive treatment
was associated with a lower rate of new-onset diabetes
(38%). Even after adjustment for the new diabetes onset
with prior antihypertensive treatment, baseline glycemia, the
Framingham risk score, baseline and in-treatment blood
pressure levels, high-density lipoprotein cholesterol, uric
acid, and body mass index, and the decreased incidenceExperimental Diabetes Research 5
of diabetes onset associated with losartan-based therapy
(26% lower risk of new diabetes onset), which occurred in
parallel with the in-treatment left ventricular hypertrophy
amelioration or absolute resolution, remained statistically
signiﬁcant [51].
2.5. The Genetic Pathophysiological Substrate of the ECG in
Diabetes and CAN. Genetic variants in myocardial sodium
and potassium channel genes in previously identiﬁed candi-
date genes may be associated with the QT interval duration,
the presence of cardiovascular autonomic dysfunction, and
theincreased risk ofsuddencardiacdeathin individualswith
diabetes [52].
2.6. Vectorcardiography: New Markers in the Aid of the ECG
Diagnosis of Diabetic Cardiomyopathy. The spatial QRS-T
angle is the ECG integral of the heart’s ventricular gradient
[53], which quantiﬁes the deviation between the directions
of the ventricular depolarization and repolarization [54].
The spatial QRS-T angle represents a global measure of
the variations of ventricular action potential durations and
morphology and, therefore, serves as a reliable and easy to
measure with modern electrocardiographs ECG marker of
arrhythmia vulnerability[55].Duetoitselectrophysiological
substrate, the spatial QRS-T angle has been proven to be a
more sensitive and of higher cardiovascular predictive value
marker than the QT interval and its parameters [56, 57].
Spatial QRS-T angle values were demonstrated to be
higher (by almost 2-fold) in patients with diabetescompared
to patients without diabetes. Higher spatial QRS-T angle
valueswerealsoindependentlyassociated with glycemiccon-
trol and impaired left ventricular myocardial performance
in patients with type 2 diabetes [58]. Moreover, in patients
with type 1 diabetes during hypoglycemia, where the QTc
interval or the QT dispersion remained unimpaired, the
morphology of the spatial QRS-T angle changed signiﬁ-
cantly, indicating increased arrhythmia vulnerability. The
increase in the spatial QRS-T angle values was independent
from any changes in catecholamine levels or in the heart rate
of the patients with type 1 diabetes [59]. The prognostic
importance of the higher spatial QRS-T angle values in
subjects with diabetes, however, remains to be evaluated in
future prospective studies. Table 1 summarizes major and
recent studies addressing the clinical signiﬁcance of the
ECG markers in the diagnosis of Diabetic Cardiomyopathy
and Silent Myocardial Ischemia in both type 1 and type 2
diabetes.
3.Cardiac Autonomic Neuropathy in Diabetes:
The “Queen’s Mirror”of Cardiovascular
MorbidityandMortality
Physiological cardiovascular activities are under the control
of the cardiac autonomic nervous system. Damage to the
autonomic nerves that innervate the heart and blood vessels
results in dysfunction in heart rate control and vascular
dynamics, in other words in CAN [60]. Autonomic imbal-
ance between the sympathetic and parasympathetic nervous
systems’ regulation of cardiovascular function contributes
to metabolic abnormalities [61] and signiﬁcant morbidity
and mortality for individuals with diabetes [62]. CAN
embraces exercise intolerance, intraoperative cardiovascular
liability, orthostatic tachycardia and bradycardia syndromes,
and silent myocardial ischemia [63]. All these clinical
manifestations canresultinlife-threateningoutcomes,which
unquestionably associate the presence of CAN with the
increased risk of cardiovascular morbidity and mortality in
diabetes [64]. This is in agreement with recent published
results from the Action to Control Cardiovascular Risk in
Diabetes (ACCORD) trial, which demonstrated that the
presenceofCANatbaseline isanindependentcontributorto
the higher cardiovascular mortality risk in both the intensive
and standard glycemic arm treatment. No diﬀerential eﬀect
was found in subgroups deﬁned by variables anticipated
to have an interaction, that is, age, duration of diabetes,
and previous history of cardiovascular disease [64, 65].
Furthermore, individuals with baseline CAN were 2 times
more likely to die compared with individuals without
CAN [65]. In addition, CAN in the presence of peripheral
neuropathy was the strongest predictor of cardiovascular
mortality [66].
CAN often coexists with peripheral neuropathy [60, 67,
68],andrecentstudiesdemonstrated thatcombiningindexes
of autonomic and peripheral neurological dysfunction, is
associated with an earlier detection and probably prevention
of the cardiovascular risk and mortality in diabetes [69,
70]. Finally, recently it was demonstrated that presence of
CAN predicts development of large-ﬁber dysfunction, and
may account for the high mortality rate in patients with
peripheral neuropathy, emphasizing the importance of early
detectionofbothCANand peripheral neuropathyto address
the cardiovascular risk in diabetes [71]. In the EURODIAB
Prospective Complications Study, peripheral and autonomic
neuropathy was among the strongest risk markers for future
total and cardiovascular mortality exceeding the eﬀect of the
traditionalriskfactors,thatis,age,obesity,hypertension,and
dyslidemia [72].
4.DiagnosticsTestsforthe Assessment of
CardiacAutonomicNeuropathy
The Golden Standard in clinical autonomic testing remains
the cardiovascular reﬂex tests. These tests have good sen-
sitivity, speciﬁcity, and reproducibility and are noninva-
sive, safe, well standardized, and easily performed [87].
Exception is the Valsalva maneuver, which must not be
performed in patients with proliferative retinopathy [88].
The most widely used tests assessing cardiac parasympa-
thetic function are based on the time-domain heart rate
response to deep breathing, the Valsalva maneuver, and
postural change. Of these tests, heart rate response to deep
breathing has the greatest speciﬁcity [89, 90]. Cardiovascular
sympathetic function is assessed by measuring the blood
pressure response to orthostatic change and the Valsalva
maneuver [91, 92]. The performance of these tests should
be standardized, and the inﬂuence of confounding variables
such as medications, hydration, and antecedent activity
should be minimized. Age normative values should be used.6 Experimental Diabetes Research
Table 1:Recent andmajorstudies oftheincidence ofelectrocardiographic abnormalitiesin diabetes andtheir endpointclinicalsigniﬁcance.
Reference Population ECG marker Clinical signiﬁcance Clinical points
Left ventricular hypertrophy and atherosclerosis in diabetic cardiomyopathy
[14] 996 T2D patients
↑ 1SD P-wave duration
≥40msec
↑ 1SD PR-interval
duration ≥12msec
↑ 1SD P-wave terminal
force
↑ Pericardial fat
No associationafter
adjustment with
adiposity indexes and
CVD risk factors
[15] 110 T2D patients, age
20–80 years
↑ Cornell Voltage∗
↑ QRS duration
Left ventricular
hypertrophy Ongoingtrial
[16] 9.193 T2D +
hypertension
↑ Cornell and Sokolow
Lyon Voltage
Left ventricular
Hypertrophy
Hyperuricemia as a
CVD risk factor
[17] 276 T2D + hypertension
↑ Cornell and Sokolow
Lyon Voltage
Left ventricular
Hypertrophy
↓ in LVH prevalence
with candesartan
[51] 9.000 hypertensive ↑ Cornell Voltage Left ventricular
Hypertrophy
38% ↓ risk of new
diabetes onset
[18] 886 T2D patients
↑ Cornell and
Sokolow-LyonVoltage
left ventricular strain
Left ventricular
hypertrophy
Coexistence of
hypertension
[42] 1.123 T2D patients ↑ QTc, ↑ QRS, ↑ JT Coronary artery
calciﬁcation men > women
Silent myocardial ischemia and cardiovascular disease risk
[26]
3.224 with diabetes,
61.9% women, mean age
72 years
minor nonspeciﬁc
ST-segment T-wave
abnormalities
↑ risk for coronary heart
disease mortality
↑ risk for primary
arrhythmic death
No association with
incident nonfatal
myocardial infarction
[27] 493 post-MI, T2D
patients
↑ T-wave alternans
≥47microV
↑ risk of sudden cardiac
death —
[35] 2.654 men, T2D patients
↓ ST segment ≥1mmfor
0.08sec
16-y CVD and all-cause
mortality
Independent of other
CVD risk factors
[41] 994 T2D patients
↓ ST segment ≥50micro
VQ T c> 460ms, PCA
ratio ≥30%
↑ CVD morbidity and
mortality ↑ all-cause
mortality
—
[28] 1.387 T2D patients Q-wave Clinically unrecognized
MI
Coexistence of
hypertension +
nephropathy
[25] 1.123 T2D patients Adenosine induced
ST-depression
Silent myocardial
ischemia 4-fold ↑ 5-years risk
[39] 472 T2D patients
↑ QT dispersion, QTc
maximum
Prognostic marker CVD
mortality
57 months follow-up ↓
prognostic value in
patients without CVD
[40] 216 T2D patients ↑ QT dispersion ↑ CVD
↑ total and
cerebrovascular
mortality
Type 1 diabetes and diabetic cardiomyopathy
[43] 22 T1D patients, mean
age 30 years
↓ QRS <120mse, QTc
≥450ms, ↑ QT
dispersion >70ms
↓ parasympathetic to
sympathetic tone ratio,
tachycardia, shortening
of the activation time
—
[46] 1.415 T1D patients QTc >440msec ↑ 7-year CVD risk
↑ risk in women,
hypertension,
hyperglycemia, CAN, ↓
risk in BMI, physical
activity
[46] 3.250 T1D patients QTc > 440msec, QT
dispersion
3-fold ↑ risk of Left
Ventricular Hypertrophy
Association with female
sex, obesity,
hypertension, physical
inactivityExperimental Diabetes Research 7
Table 1: Continued.
Reference Population ECG marker Clinical Signiﬁcance Clinical points
[47] 523 T1D and T2D
patients
↑ QTc, ↑ HR 23-years total mortality Increased Risk for T1D:
QTc; for T2D: HR
[44] 21 T1D patients ↑ QTc Marker of spontaneous
hypoglycemia
Modest increase in QTc
and misleading results in
investigations of
spontaneous
hypoglycemia
Spatial vectorcardiography in diabetic cardiomyopathy
[58] 74 T2D patients ↑ spatial QRS-T angle Diabetic
cardiomyopathy
Association with
glycemic control,
dyslipidemia
[59] 16 T1D patients ↑ spatial QRS-T angle Marker of hypoglycemia,
arrhythmia vulnerability
Independent from
catecholamine levels and
heart rate variability
SD: standard deviation; CVD: cardiovascular risk; LVH: left ventricular hypertrophy; MI: myocardial infarction, T2D: type 2 diabetes; T1D: type 1 diabetes;
QTc: QT interval corrected for heart rate; PCA ratio: principal component analysis (PCA) of the ratio of the second to ﬁrst eigenvalues of the T-wave, HR:
heart rate.
As already mentioned, the combination of cardiovascular
autonomic tests with sudomotor function tests may allow a
more accurate diagnosis of CAN [69, 70].
Among the CAN testing for clinical trials and research,
the time-domain heart rate tests and the blood pressure
response to postural change have the necessary repro-
ducibility and have been previously used as trial end-
points, that is, in the Diabetes Control and Complications
Trial/Epidemiology of Diabetes Interventions and Compli-
cations Study (DCCT/EDIC) [93] and in other clinical trials
[94, 95]. Frequency-domain indexes obtained by applying
spectral analysis to heart rate variability of short (5–7min)
andlonger(24-h)electrocardiogram recordings[96]pr o vide
a measure of sympathetic and parasympathetic modulation
ofheart rate. Heart rate spectral power in the high-frequency
region is a measure of parasympathetic modulation, while
spectral power in the low-frequency region provides a mea-
sure of both sympathetic and parasympathetic modulation.
The low-frequency blood pressure variability may provide a
measure of sympathetic modulation. To correctly assess the
signiﬁcance of the diﬀerent regions, respiration should be
measured or controlled breathing performed.
The Neuropad test is a modern indicator test, which
its performance is based on the measurement of sweat
production after exposure to dermal foot perspiration, is a
valuable tool in the diagnosis of both peripheral [69]a n d
autonomic neuropathy in patients with diabetes [70], and
appears to bea very simple and useful indicator for screening
patients with diabetic neuropathy [97]. The high degree of
reliability and easiness of the Neuropad test suggest that
it is proper even for self-testing for the identiﬁcation of
autonomic neuropathy [98].
QT interval prolongation is an independent predictor of
mortality in patients with diabetes and is associated with
CAN[62]. The pathogenesis of QT prolongation is multifac-
torial, and its correlates include female gender, nephropathy,
coronary heart disease, glycemic control, systolic blood
pressure, physical activity, and body mass index. In the
recentACCORDtrial,assessment ofCANincludedheart rate
(reﬂecting overall autonomic function and cardiorespiratory
ﬁtness), measures of heart rate variability, and the QT
interval (reﬂecting mainly sympathetic function) computed
from 10-s resting electrocardiograms [64].
5.TheECGinCardiacAutonomicNeuropathy
5.1. The ECG as an Early Marker of CAN. Early markers
of CAN in an ECG include elevated R-wave amplitude,
prolongation of QTc interval, and decreased heart rate
variability [99]. Aerobic exercise training in Zucker Diabetic
Fatty rats, a model of type 2 diabetes, although it did
not attenuate neither QT or QTc interval prolongation,
or restored decreases in heart rate variability, however, it
restored R-wave amplitude alterations and, therefore, had
a beneﬁcial eﬀect in regards to ECG correlates of the left
ventricular mass hypertrophy [73].
Even in healthy individuals, hyperinsulinemia-induced
hypoglycemia can prolong the QTc interval and decrease T-
waveareaandamplitude.Counterregulatorynorepinephrine
response correlated with QTc interval prolongation, and
epinephrine response correlated with ﬂattening of the T-
wave. Besides ECG alterations in depolarization and repo-
larization, hyperinsulinemic hypoglycemia with consequent
sympathetic humoral activation can be associated with
alterations in atrioventricular conduction and moderate ST-
segment depression [76].
5.2. Associations between the ECG Markers, Metabolic and
Other Factors in the Presence of CAN. Among the factors
signiﬁcantly associated with cardiac autonomic dysfunction
are central obesity, hypertension, smoking, hyperglycemia,
dyslipidemia, and presence of microvascular complications,
thatis,retinopath y ,nephropath y ,andpubertaldiabetesonset
in patients with type 1 diabetes. In type 2 diabetes patients,
CAN has been independently associated with central obe-
sity, hypertension, hyperglycemia, known diabetes duration,8 Experimental Diabetes Research
dyslipidemia, smoking, and presence of microvascular com-
plications, as well as with peripheral vascular disease [100].
CAN, together with diabetes duration, has been demon-
strated as the main predictor of reduced aortic distensibility
in type 2 diabetes, and, therefore, it is associated with a
signiﬁcant reduction in the elastic properties of the aorta
[101]. Reduced aortic distensibility predicts cardiovascular
mortality in patients with type 2 diabetes and impaired
glucose tolerance [102].
Accordingly, QTc interval prolongation has been associ-
ated with age, gender, systolic and diastolic blood pressure,
body mass index, central obesity, smoking, the type and
the duration of diabetes, the diﬀerent types of antidiabetic
medication, glycemic control, and the severity of autonomic
neuropathy. Major degrees of autonomic neuropathy were
found to be independent predictors of QTc interval in both
type 1 and type 2 diabetes [82, 103]. These ﬁndings were
recently further conﬁrmed in a population of patients with
both type 1 and type 2 diabetes and presence of CAN,
where QTc interval prolongation was signiﬁcantly associated
with older age, longer (>10 years) diabetes duration, and
the presence of peripheral neuropathy. Higher scores of
cardiac autonomic dysfunction also correlated with longer
QTc intervals in both type 1 and type 2 diabetes patients
[78].
5.3. The Pathophysiological Substrate That Possibly Elucidates
the Association of Cardiac Autonomic Neuropathy with Coro-
nary Heart Disease Events. The increased risk of coronary
heart disease events in diabetes presents an altered circadian
distribution with an absent morning peak and a higher
infarction rate during the evening hours. To elucidate the
mechanism of this phenomenon, and the pathophysiolog-
ical substrate behind increased cardiovascular risk in the
presence of CAN in patients with diabetes, several studies
addressed the circadian pattern of heart rate variability in
diabetes complicated with CAN.
The circadian patternof indexes ofparasympathetic tone
has been evaluated using 24h heart rate variability analysis
in conjunction with the circadian changes of ﬁbrinolytic
and hemostatic factors (plasminogen activator inhibitor 1,
factorVII,ﬁbrinogen, and factorvonWillebrand) inpatients
with type 1 diabetes and presence of CAN. CAN was
associated with a loss of both the nocturnal predominance
of parasympathetic activity, due to a small but signiﬁcant
increase of the sympathetic tone during nighttime, and
a prothrombotic state that persisted throughout the day
[104]. These abnormalities possibly attenuate the relative
protection from coronary events during the afternoon and
nighttime in patients with diabetes and CAN.
In patients with diabetes, but without CAN, a day-night
modulation of the QTc interval has been evidenced and
is dependent on both variations in the cardiac autonomic
tone and the concentrations of circulating catecholamines
[105]. This long-term modulation is signiﬁcantly diﬀerent
in subjects with diabetes in the presence of CAN, where a
circadian sympathovagal balance reverses the day-night ECG
pattern and increases nocturnal QT rate dependence [106].
Accordingly,the circadian rhythmicity of the QT interval
in patients with diabetes and varying degrees of CAN was
found to exhibit a signiﬁcant day-night periodicity. QTc
interval was longer between midnight and early in the
morning, and it was shorter in the hours after waking. These
alterations were also signiﬁcantly associated with the severity
of CAN [107].
Therefore, even in patients with diabetes and mild
parasympathetic denervation,Q Ti n t e r v a lh e a r tr a t ed e p e n -
dence is impaired. These changes in cardiac electrophys-
iological activity may be related to the reported diurnal
pattern of ventricular arrhythmias [107, 108]. The potential
prognostic impact of this reversed day-night pattern with
steep nocturnal QT/heart rate relation was assessed in later
studies.
5.4. The ECG Pattern in Cardiac Autonomic Neuropathy and
Diabetes, and Its Predictive Value. The association between
QT interval prolongation and the risk of dying unexpectedly
in patients with diabetes and CAN has been repeatedly
evaluated. Prolonged QTc interval has been signiﬁcantly
associated with the presence of CAN and the 3-year preva-
lence of sudden cardiac death in male patients, under 60
years of age, with diabetes and varying degrees of cardiac
autonomic dysfunction. This relationship was independent
of the eﬀect of age and diabetes duration. QTc not only was
signiﬁcantly longer in the patients with diabetes who died
unexpectedly, but furthermore the changes in the QT length
during follow-up where parallel with the alterations in the
cardiac autonomic function [83].
QTc interval and QT dispersion were also determined as
independent predictors of cardiovascular mortality through-
out a 12-year follow-up period of 192 patients with type
2 diabetes. Their predictive value was superior to that of
the heart rate variation in response to deep breathing and
standing and the ankle-brachial pressure index [79].
In the MONICA/KORA Augsburg Cohort Study, during
a 9-year follow-up, reduced heart rate variability and pro-
longed QTc interval (>440ms) were independent predictors
ofa2-foldand3-foldincreased riskofmortality,respectively,
in the general population (aged 55 up to 74 years) with
or without diabetes. However, increased QT dispersion
(>60ms) did not predict mortality. From the heart rate
variability parameters, low heart rate variability during
spontaneous breathing tended to be associated with excess
mortality in the people with diabetes, but not in those
without diabetes [77].
Inarecentcasecontrolstudyof682peoplewithcoronary
heart disease and diabetes but no history of sudden cardiac
death, prolongation of QTc interval was a signiﬁcant pre-
dictor of sudden cardiac death even among individuals with
a normal or borderline QTc interval. However, idiopathic
abnormal QTc interval prolongation was associated with a
higher (5-fold) increased risk of sudden cardiac death [74].
Nevertheless, the association of high resting heart rate,
with sudden cardiac death in diabetes cannot be fully
explained by the reported association between QT interval
and heart rate with coronary heart disease or left ventricular
dysfunction, the major pathological substrates for suddenExperimental Diabetes Research 9
cardiac death. Ventricular arrhythmia is the most common
antecedent event before sudden cardiac death [109]a n d
earlier[110]aswell asrecentstudies[111]examined possible
associations between resting QT interval, resting heart rate
and ventricular arrhythmogenesis.
O n es t u d yi n v e s t i g a t e dt h ep r e s e n c eo fv e n t r i c u l a rl a t e
potentialsderivedfrom signal-averagedECGin patientswith
type 1 diabetes with and without CAN, without clinical
evidence of cardiovascular disease. The QTc interval was
signiﬁcantly prolonged in patients with autonomic dysfunc-
tion as compared with those without CAN. Moreover, in the
group without CAN, there was no signiﬁcant prolongation
of the QTc interval. Ventricular late potentials were present
in patients with diabetes and were associated with isolated
presence of peripheral neuropathy but not with the presence
of CAN [80].
However, another previous study also aimed to assess the
inﬂuence of cardiovascular complications on the occurrence
of ventricular late potentials in children with type 1 diabetes
and an average course of diabetes duration of 6.5 years. Ven-
tricular late potentialswere discovered in 17% ofthe patients
with type 1 diabetes and were associated with the incidence
of left ventricular hypertrophy, longer duration of diabetes,
and the presence of CAN. Left ventricular hypertrophy,
diabetes duration, and cardiac autonomic dysfunction were
also the strongest independent parameters of ventricular
late potentials occurrence. The presence of cardiovascular
complication had no inﬂuence on ventricular late potential
occurrence in children with diabetes [112].
Finally, one recent study included 867 patients (age ≤60
years, 57% females and 17% with diabetes) who underwent
24h ambulatory ECG recording (Holter) and also examined
possible associations between resting heart rate with factors
involved in ventricular arrhythmogenesis, that is, ventricu-
lar late potentials detected by signal-averaged ECG, heart
rate variability, and premature ventricular complexes. High
resting heart rate was signiﬁcantly associated with positive
ventricular late potentials, depressed heart rate variability
indices, and increased prevalence of premature ventricular
complexes during the 24h recording, independently from
demographic and clinical variables including left ventricular
ejection fraction, and history of coronary heart disease,
or presence of ST-depression in Holter analysis. Therefore,
high resting heart rate and its inﬂuence on the cardiac
electrophysiological cycle are independently associated with
ventricular arrhythmogenesis [109]. The diﬀerent results
observed in this study compared with those of previ-
ous studies may be associated with the inability of the
QT interval to assess primary factors that contribute to
the ventricular repolarization (i.e., heterogeneity of action
potential morphology throughout the ventricles) in the
presenceof secondary factors also contributingtothecardiac
electrophysiological cycle (i.e., heterogeneity in ventricular
depolarization instants) [113].
5.5. Factors Associated with Amelioration of the ECG Alter-
ations in Cardiac Autonomic Neuropathy and Diabetes. In
the Diabetes Control and Complications Trial/Epidemiology
of Diabetes Interventions and Complications study (DCCT/
EDIC), a prospective observational follow-up of the original
DCCT type 1 diabetes cohort, cardiovascular autonomic
measures (heart rate variation during deep breathing, Val-
salva ratio, postural blood pressure changes, and autonomic
symptoms) were repeated in 1.226 patients after 14 years of
follow-up. Although, the prevalence of CAN was increased
in both therapy groups, it was signiﬁcantly lower in the
intensive therapy versus the conventional therapy group
(29% versus 35%). Heart rate variability was signiﬁcantly
greater (R-R interval variation >15) in former DCCT
patientsunderintensiveantidiabetictreatmentversusformer
DCCT patients in the conventional therapy arm.
Moreover, symptoms consistent with cardiac autonomic
neuropathy dysfunction in the 13th or the 14th EDIC year,
although seldom reported, were more prevalent in patients
in the conventional prior DCCT therapy compared to the
intensive DCCT therapy arm. In respect, among the most
commonly reported symptoms, decreased adrenergic aware-
ness of hypoglycemia was reported in 25% of the conven-
tional versus20%oftheintensive therapygroup;male impo-
tence was determined in 23% of the prior DCCT intensive
therapy versus 30% of the intensive therapy sector. Finally,
excessive postprandial epigastric fullness had no signiﬁcant
diﬀerence between the two groups. No signiﬁcant treatment
group diﬀerences were found for the rest of the symptoms.
Metabolic memory was assessed for the incidence of
abnormal R-R variation, abnormal Valsalva ratio and abnor-
mal cardiac autonomic function during EDIC, in those
subjects who were free of the condition at the end of the
DCCTstudy.PriorDCCTintensivetherapyreducedtherisks
of incident cardiovascular autonomic dysfunction by 31%
andofincidentabnormalheartratevariability(R-Rvariation
<15) by 30% in patients with type 1 diabetes in the 13th or
the 14th EDIC year.
In conclusion, the beneﬁts of intensive therapy extend
to measures and symptoms of CAN up to 14 years after the
DCCT closeout [75].
5.6. The ECG Pattern in Autonomic Dysfunction and Its Role
inDiabetesDevelopmentinHealthyPeople. Aspreviouslyref-
erenced, cardiac autonomic dysfunction has been correlated
with fasting insulin and glucose, independent of clinically
diagnosed diabetes. In a general population prospective
study, people with high resting heart rate and low heart
rate variability had increased risk for future development of
type 2 diabetes. In respect, participants in the uppermost
(>73 beats per minute) versus the lowest (≤60 beats per
minute) quartile of heart rate had a 60% increased risk of
developing diabetes. Results were similar when the sample
was restricted to participants with normal fasting glucose
at baseline or when adjusted for baseline glucose levels.
Further adjustment for age, race, gender, education, alcohol
drinking, current smoking, prevalence ofcoronary heart dis-
ease, physical activity, and body mass index demonstrated a
sustainedsigniﬁcantrelationshipbetweencardiacautonomic
dysfunction and development of diabetes [81].
5.7. The Alternative Choice of Vectorcardiography in Cardiac
Autonomic Neuropathy and Diabetes. Although the classical10 Experimental Diabetes Research
Table 2: Recent and major studies of the incidence of electrocardiographic abnormalities in cardiac autonomic neuropathy.
Reference Population/Animals ECG marker Clinical signiﬁcance Clinical points
Classical ECG markers in CAN and diabetes
[73] Zucker Diabetic Fatty
rats
↑ Rw a v ea m p l i t u d e ,
↑ QT intervals,↓ HRV
Early diagnosis of CAN,
Diabetic
Cardiomyopathy
Beneﬁcial eﬀect of
aerobic exercise in R
wave amplitude
[74] 682 T2D + coronary
heart disease
↑ QTc
↑ risk for sudden cardiac
death
Idiopathic QT
prolongation:5-fold ↑
risk of SCD
[75] 1.226 T1D patients ↓ QTc
↓ incidence of CAN with
intensive diabetic
treatment
14 years follow-up
endpoint
[76] 18 healthy subjects,
30–40 years
↓ PR, ↑ QTc, ↓ T-wave
amplitude, ↓ ST
Early diagnosis of CAN,
Arrhythmia
severe arrhythmias and
“dead-in-bed” syndrome
in unrecognized
hypoglycemia
[77] 1.720 T2D patients
+h e a l t h y
QTc > 440msec,
↓ HRV
↑ mortality
↑ QT dispersion not
signiﬁcantpredictor
[78] 100 T1D and T2D
patients
↑ QTc CAN
Association with age,
diabetes duration,
severity of CAN
[79] 192 T2D patients ↑ QTc, ↑ QT dispersion 12-y CVD risk Superior to ABI, CAN
test for CVD risk
[80] 80 T1D patients ↑ QTc CAN Absence of ventricular
late potentials in QTc
[81] 8.185 healthy people
↓ HRV and ↑ Heart
Rate > 73bpm 60% ↑ risk of T2D
Independent of CVD
disease, age, gender, life
and style
[82] 105 T1D and T2D
patients
↑ QTc > 440msec
↑ CAN severity (Ewing
score)
Association with age,
obesity, hypertension,
diabetes duration and
control, diabetic
treatment
[83] 26 males with diabetes ↑ QTc
↑ 3-year SCD risk in
CAN
Independent of age,
diabetes duration
Vectorcardiography: the alternative proposition in CAN and diabetes
[84] 5.781, age ≥ 55 years,
12.7% with diabetes
Spatial QRS-T angle ≥
75◦
4-fold ↑ risk of 4-year
CVD and SCD
3-fold ↑ risk of fatal and
nonfatal CVD events
[85] 4.173, 14% with diabetes Spatial QRS-T angle ≥
45◦
50% ↑ risk of 7-year
incident CVD
50% ↑ risk of 7-year
total mortality
[56] 6.134, 10% with diabetes Spatial QRS-T angle ≥
105◦
5-fold ↑ risk of CVD
death
2-fold ↑ risk of SCD and
total mortality
[86] 142 women, 32% with
diabetes
Spatial QRS-T angle ≥
49◦
1.5-fold ↑ risk of CVD
events 3-year prospective study
[3] 232 T2D patients ↑ spatial QRS-T angle
↑ incidence of CAN
↑ incidence of Diabetic
Cardiomyopathy
Association with HRV
(↓parasympathetic tone
and ↑ sympathetic tone
or sympathovagal
imbalance)
CAN: cardiac autonomic neuropathy; T2D: type 2 diabetes; T1D: type 1 diabetes; HRV: heart rate variability;QTc: QT interval corrected forheart rate;S C D :
sudden cardiac death; CVD: cardiovascular disease;ABI: ankle-brachialindex.
ECG parameters has been repeatedly used for the assessment
of repolarization abnormalities in diabetes and presence of
CAN, they have also been frequently criticized as poor indi-
cators of ventricular arrhythmogenicity [114, 115]. More-
over, not all studies reached in similar conclusions regarding
the association between prolongation of the QT interval
and presence of cardiac autonomic dysfunction [116–118].
Furthermore, calculation of the classic ECG parameters is
often time consuming, subjected to methodological errors,
and is also aﬀected by heart rate [115].Experimental Diabetes Research 11
30ms
40ms
H
Pmax: 75.5µV, −6◦
QRS max: 1465.3µV, −13◦
T max: 321.6µV, 31◦
Hl o o p
Figure 3: The resting vectorcardiogram of a 56-years old male
subject with type 2 diabetes and cardiac autonomic neuropathy
recorded with the help of a computer-based 12-lead ECG system
andautomaticallyanalyzed by the Modular-ECG-Analysis program
incorporated in the electrocardiograph. The amplitude of the mean
spatial T-vector (red line vector) and the amplitude of the mean
spatial QRS-vector (yellow line vector) form an angle of 52◦ (violet
line between the two spatial vectors), which deﬁnes the patient’s
spatial QRS-T angle.
As previously mentioned, the spatial QRS-T angle is a
modernECGmarker aiming toassess theoverallheterogene-
ity of ventricular action potential morphology [119]. It is
obtained by vectorcardiography and can be computedon the
basis of a regular routine 12-lead ECG [55]; determination
of the spatial QRS-T angle has many advantages over the QT
interval measurement; it can be obtained easily and faster by
the newer ECGs equipment, it is not subjected to calculation
errors or aﬀected by heart-rate, it is of low cost, and it has
been evaluated prospectively.
In the Rotterdam Study [56, 84], the spatial QRS-T angle
was an important arrhythmogenic marker for subclinical
myocardial damage. Abnormal spatial QRS-T angle values
(≥105◦) were found in 20% of the subjects with type 2
diabetes and were associated with increased risk of cardiac
mortality and sudden cardiac death. The risks associated
with a borderline spatial QRS-T angle (<75◦)w e r ea l s o
signiﬁcantly increased for all outcomes. In the WISE Study
[86],type2diabeteswasassociated with widerspatial QRS-T
angles values (>49◦), which predicted adverse cardiovascular
eventsindependentlyoftheseverityofcoronaryheartdisease
in subjects with suspected myocardial ischemia. Smaller
values of spatial QRS-T angle (<49◦)w e r ea l s op r e d i c t i v e
ofcardiovascular eventsinhealthy individuals. Furthermore,
in the Cardiovascular Health Study [85], a widening of the
spatial QRS-T angle (>45◦) was associated with a higher
proportion (19%) of silent myocardial infarction in type 2
diabetes subjects free from coronary heart disease. Figure 3
illustrates the vectorcardiogram of a patient with type 2
diabetes and cardiac autonomic neuropathy in the absence
of QTc interval or QT dispersion prolongation as measured
in the patient’s resting 12-lead ECG pattern.
One recent study demonstrated that the spatial QRS-T
angle is signiﬁcantly wider in subjects with type 2 diabetes
and CAN [118]. Moreover, presence and severity of CAN
were the strongest predictors of the spatial QRS-T angle
values. Heart rate variability parameters were signiﬁcantly
and independently associated with the spatial QRS-T angle.
The ﬁndings of this study support that preservation of
the parasympathetic function in type 2 diabetes and CAN
is protective, while sympathetic predominance or sympa-
thovagal imbalance are harmful for the heart’s normal
electrophysiological activity and result in alterations in the
spatial QRS-T angle. Additionally, from the clinical point of
view, a wider spatial QRS-T angle in uncomplicated subjects
with type 2 diabetes may point out to the presence of CAN,
which is often underdiagnosed.
Besides the autonomic inﬂuences on the heart’s electro-
physiological activity, a wider spatial QRS-T angle reﬂects
damaged areas of the myocardium that distort the spread
of electrical forces through the myocardial wall [120].
Wider spatial QRS-T angle values were also signiﬁcantly
and independently associated with increased left ventricular
mass and worse left ventricular myocardial performance
in the patients with type 2 diabetes. Noteworthy, heart
rate variability parameters explained almost 50% of the
spatial QRS-T angle variability, suggesting presence of a
pathophysiologicalground linking thestructural, functional,
and electrical myocardial disturbances in type 2 diabetes.
T h e s ed i s t u r b a n c e sw e r ee v e nm o r ee x a c e r b a t e db yt h e
presence of cardiac autonomic dysfunction [118]. Table 2
summarizes major and recent studies evaluating the clinical
signiﬁcance of the ECG pattern in diabetes and the presence
of Cardiac Autonomic Neuropathy.
6.ConclusionRemarksand Thoughts
Currently ongoing research has revealed that in diabetic
cardiomyopathy direct metabolic alterations of the cardiac
myocyte and impaired support of extra cardiac factors
regulating cardiac activity, such as sympathetic regulation
of heart rate and contractility, are involved in the diﬀerent
alterations of the cardiac ionic currents in the heart and
the provocation of arrhythmia, mainly by the reduction
in potassium repolarizing currents [121, 122]. Cardiac
autonomic neuropathy leads to diminished noradrenaline
release in cardiac ventricle in response to diﬀerent external
or internal stimulus, that is, standing, exercise or stress
[123]. Reduction of the cardiac myocyte response to acute
noradrenaline exposure and, ﬁnally, impairment of diﬀerent
trophicfactorsresponsible fortheregulationofionicchannel
expression due to diabetic cardiomyopathy [124]a r ea l l
involved in the vulnerability and increased incidence of
cardiac arrhythmia of the diabetic heart.
I nt h i se r a ,t h eE C Gc o n t i n u e st ob ea ni n v a l u a b l et o o li n
the initial evaluation of patients with diabetes. The plethora
of data currently available on ECG changes correlating with
diabetic cardiomyopathy and cardiac autonomic neuropathy
allows clinicians tomakefaster and betterdecisionsthan ever
before. Even early in the course of diabetes, ECG alterations
of the rhythm, beginning from simple sinus tachycardia and
moving ontodiﬀerentECGparametersliketheprolongation
of the classical QTc interval, or the QT dispersion, and the12 Experimental Diabetes Research
Resting 12-lead ECG 
Evaluation of:
Rhythm: presence of sinus tachycardia, arrhythmia
Rare: presence of silent atrial fibrillation
Length of QT interval and correction for heart rate
 Altered heart rate variability
QT interval parameters: QT maximum, QT minimum, QT dispersion
Presence of early left ventricular hypertrophy: Sokolow-Lyon/Cornell voltage
Presence of ECG atherosclerotic and metabolic atrioventricular conduction alterations: 
 prolongation of P-wave and PR-interval
P-wave amplitude and morphology alterations
Presence of JT-wave
Width of the spatial QRS-T angle 
Exercise ECG testing
Cardiac autonomic function analysis:
resting heart rate
altered heart rate variability
24 h Holter rhythm
Ewing tests: deep breathing, lying to standing, Valsalva maneuver, 
orthostatic hypotension
Baroreflex function and sensibility 
QT interval and its parameters 
Spatial QRS-T angle 
Screening for silent myocardial ischemia
Resting ECG: ST depression, Q-wave, 
T-wave abnormalities 
Stress echocardiography
Stress myocardial perfusion images
Figure 4: Proposed Cardiovascular Examinationfor Patients with Diabetes and Cardiac Autonomic Neuropathy.
modern wider spatial QRS-T angle deviation, ST-segment
and T-wave changes, alterations in heart rate variability, and
presence of left ventricular hypertrophy, may be observed.
ECG alterations help evaluate cardiac autonomic neu-
ropathy and detect signs of silent myocardial ischemia even
in clinically asymptomatic patients with diabetes. Prolonged
myocardial ﬁbrosis leads to diabetic cardiomyopathy, with
peculiar ECG presentation. Electrocardiographic changes
are often present in children and adolescents with type
1 diabetes. The resting ECG, frequently complemented by
exercise ECG testing, is a major assistant in cardiac screening
of individuals with diabetes and cardiac autonomic neu-
ropathy and helps detect silent myocardial ischemia, assess
prognosis, and predict cardiovascular, cerebrovascular, and
all-cause mortality. As a closing remark extracted from the
referenced clinical and research studies, Figure 4 summarizes
a proposed cardiovascular examination for patients with
diabetes and cardiac autonomic neuropathy.
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